Biocure Technology Inc.

CURE

CA09075T1075

Uranium

Market Closed - Canadian Securities Exchange Other stock markets 09:30:00 2023-09-11 am EDT			5-day change	1st Jan Change
0.015 ^CAD	-25.00%		-.--%	-.--%

2023	Biocure Technology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
2023	Atriva Therapeutics GmbH announced that it expects to receive $15 million in funding	CI

Biocure Technology Inc. announced that it has received CAD 0.0541 million in funding

January 16, 2023

Biocure Technology Inc. announced a non-brokered private placement of 12,500 shares at an issue price of CAD 4.328 per share for gross proceeds of CAD 54,100 on January 17, 2023. The company holds now 93.42% interest in BPK.

Latest news about Biocure Technology Inc.

Biocure Technology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 27	CI
Atriva Therapeutics GmbH announced that it expects to receive $15 million in funding	23-09-17	CI
Atriva Therapeutics GmbH entered into a letter of intent to acquire Biocure Technology Inc..	23-09-17	CI
Biocure Technology Inc. announced that it has received $15 million in funding from Atriva Therapeutics GmbH	23-09-17	CI
Biocure Technology Inc. Announces Chief Executive Officer Changes	23-09-08	CI
Biocure Technology Inc. Announces Board of Director Changes	23-09-08	CI
Biocure Technology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Biocure Technology Inc. Announces Resignation of Berkan Unal from its Board of Directors	23-07-05	CI
Sang Mok Lee acquired 46% of stake in BiocurePharm Corporation from Biocure Technology Inc..	23-05-30	CI
Biocure Technology Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-28	CI
Biocure Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-16	CI
Biocure Technology Inc. Auditor Raises 'Going Concern' Doubt	23-05-15	CI
Biocure Technology Inc. announced that it has received CAD 0.2376 million in funding	23-01-29	CI
Biocure Technology Inc. announced that it has received CAD 0.0541 million in funding	23-01-16	CI
BiocurePharm Corporation announced that it has received CAD 0.0541 million in funding from Biocure Technology Inc.	23-01-15	CI
Biocure Technology Inc. Announces Danny Joh Resigned from Board of Directors	22-12-22	CI
Sang Mok Lee agreed to acquire 46% of stake in BiocurePharm Corporation from Biocure Technology Inc. for CAD 0.27 million.	22-12-18	CI
Biocure Technology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-25	CI
Biocure Technology Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-23	CI
Biocure Technology Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-24	CI
Biocure Technology Inc. Auditor Raises 'Going Concern' Doubt	22-04-28	CI
Biocure Technology Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-28	CI
BiocurePharm Corporation announced that it has received CAD 0.106896 million in funding from Biocure Technology Inc.	21-12-01	CI
Biocure Technology Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-29	CI
Biocure Technology Inc. Announces Focus on its own CAR T-cell Therapy Targeting Chronic Lymphocytic Leukemia and Solid Tumor Cancers and Intent to Apply for Patents	21-08-30	CI

Chart Biocure Technology Inc.

Duration

Period

More charts

Company Profile

Biocure Technology Inc. is a biopharmaceutical company. The Company is engaged in development and commercialization of various biopharmaceutical technologies relating to uses of recombinant and ranibizumab. The Company is comprised of scientists specializing in the development and commercialization of its own CAR T-cell therapy, targeting Chronic lymphocytic leukemia and solid tumor cancers. In addition, the Company is developing Biosimilar technologies for cancer treatment. The Companyâs products include Interferon Beta, Ranibizumab and PEG-Filgrastim.

Sector

Uranium

Calendar

2024-04-30 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Uranium

	1st Jan change	Capi.
BIOCURE TECHNOLOGY INC.	-.--%	1.03M
CAMECO CORPORATION	+17.98%	21.37B
URANIUM ENERGY CORP.	+7.97%	2.79B
CGN MINING COMPANY LIMITED	+13.37%	1.89B
YELLOW CAKE PLC	+1.94%	1.7B
CENTRUS ENERGY CORP.	-23.60%	665M
URANIUM ROYALTY CORP.	-9.27%	284M
ELEVATE URANIUM LTD	+3.37%	92.53M
GOVIEX URANIUM INC.	-40.00%	53.43M